Hosted on MSN13h
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 DrugInflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...
GlobalData on MSN14h
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDSThe European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...
H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...
InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary ...
JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today ...
InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...
InflaRx has commenced a Phase 2a study for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa, dosing its first patient. InflaRx N.V. has announced the initiation of a Phase 2a ...
(MENAFN- GlobeNewsWire - Nasdaq) JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti ...
JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback